Cite
HARVARD Citation
Al Efraij, K. et al. (2018). Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype. Expert review of clinical pharmacology. 11 (7), pp. 669-676. [Online].